The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras
Open accessAbstract
BACKGROUND: Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) can affect many organ systems. However, temporal changes during the coronavirus disease 2019 (Covid-19) pandemic, including the evolution of SARS-CoV-2, may have affected the risk and burden of PASC. Whether the risk and burden of PASC have changed over the course of the pandemic is unclear. METHODS: We used health records of the Department of Veterans Affairs to build a study population of 441,583 veterans with SARS-CoV-2 infection between March 1, 2020, and January 31, 2022, and 4,748,504 noninfected contemporaneous controls. We estimated the cumulative incidence of PASC at 1 year after SARS-CoV-2 infection during the pre-delta, delta, and omicron eras of the Covid-19 pandemic. RESULTS: Among unvaccinated persons infected with SARS-CoV-2, the cumulative incidence of PASC during the first year after infection was 10.42 events per 100 persons (95% confidence interval [CI], 10.22 to 10.64) in the pre-delta era, 9.51 events per 100 persons (95% CI, 9.26 to 9.75) in the delta era, and 7.76 events per 100 persons (95% CI, 7.57 to 7.98) in the omicron era (difference between the omicron and pre-delta eras, -2.66 events per 100 persons [95% CI, -2.93 to -2.36]; difference between the omicron and delta eras, -1.75 events per 100 persons [95% CI, -2.08 to -1.42]). Among vaccinated persons, the cumulative incidence of PASC at 1 year was 5.34 events per 100 persons (95% CI, 5.10 to 5.58) during the delta era and 3.50 events per 100 persons (95% CI, 3.31 to 3.71) during the omicron era (difference between the omicron and delta eras, -1.83 events per 100 persons; 95% CI, -2.14 to -1.52). Vaccinated persons had a lower cumulative incidence of PASC at 1 year than unvaccinated persons (difference during the delta era, -4.18 events per 100 persons [95% CI, -4.47 to -3.88]; difference during the omicron era, -4.26 events per 100 persons [95% CI, -4.49 to -4.05]). Decomposition analyses showed 5.23 (95% CI, 4.97 to 5.47) fewer PASC events per 100 persons at 1 year during the omicron era than during the pre-delta and delta eras combined; 28.11% of the decrease (95% CI, 25.57 to 30.50) was attributable to era-related effects (changes in the virus and other temporal effects), and 71.89% (95% CI, 69.50 to 74.43) was attributable to vaccines. CONCLUSIONS: The cumulative incidence of PASC during the first year after SARS-CoV-2 infection decreased over the course of the pandemic, but the risk of PASC remained substantial even among vaccinated persons who had SARS-CoV-2 infection in the omicron era. (Supported by the Department of Veterans Affairs.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Long COVID: major findings, mechanisms and recommendations
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00846-2 · Cited by 4,153
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Long-term cardiovascular outcomes of COVID-19
Xie, Y., Xu, E., Bowe, B., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-01689-3 · Cited by 2,029
Self-citationNegative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583
High-dimensional characterization of post-acute sequelae of COVID-19
Al-Aly, Z., Xie, Y., & Bowe, B. (2021) · Nature · doi:10.1038/s41586-021-03553-9 · Cited by 1,518
Collaborators, G. B. O. D. L. C., Wulf Hanson, S., Abbafati, C., Aerts, J. G., Al-Aly, Z., Ashbaugh, C., Ballouz, T., Blyuss, O., Bobkova, P., Bonsel, G., et al. (2022) · JAMA · doi:10.1001/jama.2022.18931 · Cited by 970
Self-citationLong COVID after breakthrough SARS-CoV-2 infection
Al-Aly, Z., Bowe, B., & Xie, Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01840-0 · Cited by 866
Self-citationAcute and postacute sequelae associated with SARS-CoV-2 reinfection
Bowe, B., Xie, Y., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-02051-3 · Cited by 639
Self-citationRisk of long COVID associated with delta versus omicron variants of SARS-CoV-2
Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S., & Steves, C. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00941-2 · Cited by 629
Unexplained post-acute infection syndromes
Choutka, J., Jansari, V., Hornig, M., & Iwasaki, A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01810-6 · Cited by 604
Risks and burdens of incident diabetes in long COVID: a cohort study
Xie, Y., & Al-Aly, Z. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00044-4 · Cited by 564
Self-citationLong-term neurologic outcomes of COVID-19
Xu, E., Xie, Y., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-02001-z · Cited by 530
Self-citationAltmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00904-7 · Cited by 389
Postacute sequelae of COVID-19 at 2 years
Bowe, B., Xie, Y., & Al-Aly, Z. (2023) · Nature Medicine · doi:10.1038/s41591-023-02521-2 · Cited by 350
Self-citationBowe, B., Xie, Y., Xu, E., & Al-Aly, Z. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060734 · Cited by 333
Self-citationRisks of mental health outcomes in people with covid-19: cohort study
Xie, Y., Xu, E., & Al-Aly, Z. (2022) · BMJ · doi:10.1136/bmj-2021-068993 · Cited by 323
Self-citationAssociation of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
Xie, Y., Choi, T., & Al-Aly, Z. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0743 · Cited by 303
Self-citationXie, Y., Bowe, B., & Al-Aly, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-26513-3 · Cited by 301
Self-citationXie, Y., Bowe, B., Maddukuri, G., & Al-Aly, Z. (2020) · BMJ · doi:10.1136/bmj.m4677 · Cited by 181
Self-citationPropensity score weighting for causal inference with multiple treatments
Li, F., & Li, F. (2019) · The Annals of Applied Statistics · doi:10.1214/19-aoas1282 · Cited by 168
Xie, Y., Choi, T., & Al‐Aly, Z. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00684-9 · Cited by 167
Self-citationSolving the puzzle of Long Covid
Al‐Aly, Z., & Topol, E. J. (2024) · Science · doi:10.1126/science.adl0867 · Cited by 142
Self-citationMolnupiravir and risk of post-acute sequelae of covid-19: cohort study
Xie, Y., Choi, T., & Al‐Aly, Z. (2023) · BMJ · doi:10.1136/bmj-2022-074572 · Cited by 111
Self-citation
Cited by
Long COVID science, research and policy
Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03173-6 · Cited by 538
Self-citationGreenhalgh, T., Sivan, M., Perlowski, A., & Nikolich, J. Ž. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01136-x · Cited by 502
Ely, E. W., Brown, L. M., & Fineberg, H. V. (2024) · New England Journal of Medicine · doi:10.1056/nejmsb2408466 · Cited by 340
Mapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Self-citation
Metadata
- Authors
- Xie, Y., Choi, T., & Al-Aly, Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-08-08
- Volume
- 391
- Issue
- 6
- Pages
- 515-525
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4400723344
- Cited by
- 267
- References
- 24
- FWCI
- 61.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.